TY - JOUR
T1 - Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness
AU - Harrington, Karra D.
AU - Lim, Yen Ying
AU - Ames, David
AU - Hassenstab, Jason
AU - Laws, Simon M.
AU - Martins, Ralph N.
AU - Rainey-Smith, Stephanie
AU - Robertson, Joanne
AU - Rowe, Christopher C.
AU - Salvado, Olivier
AU - Doré, Vincent
AU - Villemagne, Victor L.
AU - Snyder, Peter J.
AU - Masters, Colin L.
AU - Maruff, Paul
AU - the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group
PY - 2017
Y1 - 2017
N2 - Introduction High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aβ−) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aβ− group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.
AB - Introduction High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aβ−) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aβ− group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.
KW - Alzheimer disease
KW - Amyloid
KW - Cognitive aging
KW - Memory
KW - Normal aging
UR - http://www.scopus.com/inward/record.url?scp=85024374290&partnerID=8YFLogxK
U2 - 10.1016/j.dadm.2017.05.006
DO - 10.1016/j.dadm.2017.05.006
M3 - Article
AN - SCOPUS:85024374290
SN - 2352-8729
VL - 8
SP - 156
EP - 164
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
ER -
